TET2 and acute myeloid leukemia: Although also reduced by 5′-Aza treatment, ancestral AML cells carrying biallelic TET2 mutations but negative for the NPM1 mutation retained viability and presumably reacquired the ability to differentiate and recapitulate normal hematopoiesis, rendering a cytomorphological remission.